Status:
COMPLETED
Early Rivaroxaban for Acute Ischemic Stroke or TIA Patients With Atrial Fibrillation
Lead Sponsor:
General Hospital of Shenyang Military Region
Conditions:
Cerebral Infarction
TIA
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Anticoagulant treatment for non-valvular atrial fibrillation (AF) associated with cerebral infarction/ TIA is one of the recognized treatment of stroke prevention. The ACC/AHA and national guidelines ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Over 18 years
- Acute cerebral infarction caused by non-valvular atrial fibrillation
- NIHSS score ≤ 15
- Within 12 days of onset
- first stroke onset or past stroke without obvious neurological deficit (mRS score≤1)
- Signed informed consent
- Exclusion Criteria:
- Hemorrhagic stroke or mixed stroke
- Patients with valvular atrial fibrillation or non-cardiogenic cerebral infarction
- Patients with severe infection or serious diseases
- Gastrointestinal bleeding or major operation within 3 months
- Planed cerebrovascular reconstruction or cardiac surgery within 3 months
- Planed major surgery within 3 months
- Participating in other clinical trials within 3 months
- Unsuitable for this trial assessed by research
Exclusion
Key Trial Info
Start Date :
November 20 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 30 2025
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT03749057
Start Date
November 20 2018
End Date
March 30 2025
Last Update
August 21 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
General Hospital of ShenYang Military Region
Shenyang, China